134 related articles for article (PubMed ID: 11459998)
1. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
[TBL] [Abstract][Full Text] [Related]
2. Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.
van Maanen MJ; Doesburg Smits K; Damen JM; Heck AJ; Beijnen JH
Int J Pharm; 2000 May; 200(2):187-94. PubMed ID: 10867248
[TBL] [Abstract][Full Text] [Related]
3. A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH
Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.
van Maanen MJ; Smits KD; Beijnen JH
J Chromatogr B Biomed Sci Appl; 2000 Jun; 742(2):335-43. PubMed ID: 10901138
[TBL] [Abstract][Full Text] [Related]
5. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
7. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
9. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
11. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
de Jonge ME; van Dam SM; Hillebrand MJ; Rosing H; Huitema AD; Rodenhuis S; Beijnen JH
J Mass Spectrom; 2004 Mar; 39(3):262-71. PubMed ID: 15039933
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.
Huitema AD; Tibben MM; Kerbusch T; Zwikker JW; Rodenhuis S; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1998 Sep; 716(1-2):177-86. PubMed ID: 9824231
[TBL] [Abstract][Full Text] [Related]
14. Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
van Maanen RJ; van Ooijen RD; Zwikker JW; Huitema AD; Rodenhuis S; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):103-12. PubMed ID: 9869370
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
16. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate.
van Maanen MJ; Huitema AD; Beijen JH
Anticancer Res; 2000; 20(3A):1711-6. PubMed ID: 10928097
[TBL] [Abstract][Full Text] [Related]
17. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
18. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
19. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
20. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
